Company Description
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally.
It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.
The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform.
It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness.
The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
| Country | United States |
| Founded | 1979 |
| IPO Date | Nov 5, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Mark A. Emalfarb |
Contact Details
Address: 1044 North U.s. Highway One, Suite 201 Jupiter, Florida 33477 United States | |
| Phone | 561-743-8333 |
| Website | dyadic.com |
Stock Details
| Ticker Symbol | DYAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001213809 |
| CUSIP Number | 26745T101 |
| ISIN Number | US26745T1016 |
| Employer ID | 45-0486747 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark A. Emalfarb | Founder, Chief Executive Officer, President and Director |
| Ping Wang Rawson CPA, M.B.A. | Chief Financial Officer |
| Joseph P. Hazelton | Chief Business Officer |
| Doug Pace B.A. | Executive Vice President of Business Development |
| Ana Gómez Rodriguez | Secretary of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 11, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2023 | 8-K | Current Report |